首页> 外文OA文献 >Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B

【2h】

Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B

机译：第48周分析LB80380与恩替卡韦治疗初治慢性乙型肝炎患者的疗效和安全性的IIB期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

This journal suppl. contain abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011

机译：该杂志补充。包含美国肝脏疾病研究协会第62届年会的摘要：2011年肝脏会议

著录项

作者
Cho, M; Yuen, MF; Yoon, SK; Lai, CL; Lee, JW; Park, NH; Kweon, YO; Sohn, JH; Lee, J; Kim, JA; Han, KH; Um, SH; Lee, KS; Ahh, SH;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: Week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial [J] . VernazzaP., WangC., PozniakA., JAIDS: Journal of acquired immune deficiency syndromes . 2013,第2期

机译：lersivirine（UK-453,061）与efavirenz在未接受抗逆转录病毒治疗的HIV-1感染患者中的疗效和安全性：第48周的主要分析结果来自正在进行的，多中心，随机，双盲的IIb期临床研究
2. A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naive patients with chronic hepatitis B. [J] . Shin SR, Yoo BC, Choi MS, Hepatology international . 2011,第2期

机译：克列夫定和恩替卡韦在未经治疗的慢性乙型肝炎患者中48周治疗效果的比较。
3. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B [J] . LaiC.-L., AhnS.H., LeeK.S., Gut: Journal of the British Society of Gastroenterology . 2014,第6期

机译：在亚洲慢性乙型肝炎患者中，贝西福韦（LB80380）与恩替卡韦进行IIb期多中心随机试验
4. IMANI-1 TC3WP Single Drug HAART -Proof of Concept Study Pilot Study of the Safety and Efficacy of Kaletra (LPV/r) as Single Drug HAART in HIV+ ARV- Naive Patients - Interim Analysis of Subjects Completing Final 48 Week Data [C] . J.C. Gathe Jr., M. Washington, C. Mayberry International AIDS Conference . 2004

机译：Imani-1 TC3WP单药搭载概念研究试验试验研究Kaletra（LPV / R）作为艾滋病毒+ ARV天真患者单药HAART的安全性和有效性 - 临时分析受试者完成最终的48周数据
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis [O] . Pan Zhao, Weiwei Liu, Jun Zhao, 2011

机译：恩替卡韦和阿德福韦在未经HBeAg阳性的亚洲慢性乙型肝炎患者中48周疗效的比较：一项荟萃分析
7. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B [O] . Ahn, SH, Lee, J, Sohn, JH, 2013

机译：亚洲慢性乙型肝炎患者贝西福韦（LB80380）与恩替卡韦的IIb期多因素随机试验

Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B

摘要

著录项

相似文献

相关主题

期刊订阅